MedTrace Logo

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

NCT03180437 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2020-11-02

No results posted yet for this study

Summary

In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.

Conditions

Interventions

PROCEDURE

IRE surgery

IRE surgery will be used in local tumor

BIOLOGICAL

IRE plus γδ T cells

Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, PhD · Biological treatment center in Fuda cancer hospital Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2018-06-15
Completion
2019-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03180437 on ClinicalTrials.gov